Dementia is a disorder that is characterized by a decline in one or more of the cognitive functions (learning and memory, language, executive functions, attention, motor and social abilities). The dysfunctions are usually severe enough to interfere with the patient??s daily activities and independence. The main underlying cause of vascular dementia is cerebrovascular disease or insufficient cerebral microvascular circulation. The vascular dementia should be treated for vascular risk factors, especially hypertension, diabetes hypercholesterolemia, smoking and inactivity. , .The standard pharmacological interventions are Acetylcholinesterase inhibitors (donepezil, galantamine) and N-Methyl-D-aspartate receptor antagonists (Memantine). However, recovery of lost cognitive function beyond the initial recovery from vascular dementia is not likely. Moreover, Parkinson disease is another common neurological disease, caused by loss of dopaminergic neurons of substantia nigra pars compacta. The primary treatments are anticholinergics (benztropine, trihexyphenidyl), dopamine precursors (levodopa, carvidopa), COMT inhibitors (Entacapone), MAO B inhibitor (Selegiline), and Amantadine. Above treatments can slow down the disease progression but they cannot reverse the disease course. Here we are reporting a patient with dementia and parkinson??s disease who was significantly improved by ministration of PCSK9 inhibitor.
Dementia is a disorder that is characterized by a decline in one or more of the cognitive functions (learning and memory, language, executive functions, attention, motor and social abilities).[5]The dysfunctions are usually severe enough to interfere with the patient??s daily activities and independence. The main underlying cause of vascular dementia is cerebrovascular disease or insufficient cerebral microvascular circulation.[7] The vascular dementia should be treated for vascular risk factors, especially hypertension, diabetes hypercholesterolemia, smoking and inactivity.[8],[9].The standard pharmacological interventions are Acetylcholinesterase inhibitors (donepezil, galantamine) and N-Methyl-D-aspartate receptor antagonists (Memantine). However, recovery of lost cognitive function beyond the initial recovery from vascular dementia is not likely. Moreover, Parkinson disease is another common neurological disease, caused by loss of dopaminergic neurons of substantia nigra pars compacta. The primary treatments are anticholinergics (benztropine, trihexyphenidyl), dopamine precursors (levodopa, carvidopa), COMT inhibitors (Entacapone), MAO B inhibitor (Selegiline), and Amantadine. Above treatments can slow down the disease progression but they cannot reverse the disease course. Here we are reporting a patient with dementia and parkinson??s disease who was significantly improved by ministration of PCSK9 inhibitor.